Drug Database
HO

Hoe-285 (Hoe 285 / Brainorm / Albex 285)

✓ Approved

Sanofi S.A · Small Molecule · Small Molecule

What is Hoe-285?

Hoe-285 is a small molecule developed by Sanofi S.A. It is approved for therapeutic indications via injectable (others) or intravenous (iv) or oral (po).

Drug Profile

Brand NamesHoe 285, Brainorm, Albex 285
CompanySanofi S.A
Drug ClassSmall Molecule
RouteInjectable (Others), Intravenous (IV), Oral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Sanofi S.A

Therapeutic Indications

Hoe-285 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Nervous system disordersDelayed ischaemic neurological deficit✓ Approved

Related Research Articles

PubMedJournal of colloid and interface science2026-08-29

Bifunctional poly(3,4-ethylenedioxythiophene) intercalation enables interlayer engineering in nickel-iron layered double hydroxides for enhanced oxygen evolution reaction.

Chen Zih-You ZY, Chang Ling-Yu LY

Layered double hydroxides (LDHs) are promising electrocatalysts for the oxygen evolution reaction (OER); however, restricted interlayer ion accessibility and poor intrinsic electronic conductivity remain persistent limitations of conventional LDH electrodes. Herein, poly(3,4-ethylenedioxythiophene) (PEDOT) intercalation is introduced as an interlayer engineering strategy for nickel-iron layered double hydroxides (NiFe-LDHs) through sequential anion exchange (CO₃2-, Cl-, and SO₄2-), 3,4-ethylenedioxythiophene (EDOT) monomer intercalation, and in situ oxidative polymerization within the interlayer galleries. A nine-sample matrix enables systematic investigation of the effects of anion identity, EDOT intercalation, and PEDOT formation on the structural and electrochemical properties of NiFe-LDHs. X-ray diffraction (XRD) revealed a progressive basal-spacing expansion from 7.7 Å for NiFe-CO₃ LDH to 9.3 Å for NiFe PEDOT-SO₄ LDH. Among all samples, NiFe PEDOT-SO₄ LDH exhibited the best OER performance, requiring an overpotential of 285 ± 1 mV at 10 mA cm-2 and a charge-transfer resistance of 2.4 ± 0.1 Ω. This work demonstrates conducting-polymer-based interlayer engineering as a promising strategy for simultaneously tailoring ion accessibility, electrochemically accessible surface/interface, and charge transport in LDH electrocatalysts for alkaline water electrolysis.

PMID 42667858
Read full article →
PubMedACS omega2026-08-28

Enhanced Room-Temperature Phosphorescence from Carbon Dots Embedded in a Robust SiO2 Matrix.

Koswatta A C W W M N Peshala ACWWMNP, Senevirathnage Thilini Upeksha TU, Mageswari Gomathi Vinayakam GV, Tsuchiya Youichi Y et al.

Carbon dots (CDs) represent a rapidly advancing class of fluorescent nanomaterials. Due to the dominant nonradiative decay channels of the triplet excited state of CDs, these materials generally exhibit no observable phosphorescence (PH) or delayed fluorescence. Here, we report the development of a sustainable and efficient room-temperature phosphorescence (RTP) material by embedding CDs into a covalently bonded silica matrix, with both components derived from a previously unreported biomass precursor. Our effort has focused on stabilizing triplet excited states of CDs by constructing hybrid systems of CDs dispersed in SiO2 matrices, aiming to achieve heavy-metal-free RTP. In this work, we used natural coconut shells to synthesize CDs through the sol-gel method. Furthermore, we leveraged the intimate association between carbon and silica to develop CDs@SiO2. We found that calcination temperature critically influences the exciton confinement efficiency of CDs@SiO2. High-temperature calcination at 600 °C forms a highly rigid, cross-linked SiO2 network with strong Si-O-C and Si-C covalent bonds that connect to the CDs, effectively stabilizing triplet states and achieving an instrumentally fitted RTP lifetime of 285 ms and a visible afterglow duration >10 s (naked-eye detection after 365 nm excitation), and a total photoluminescence quantum yield of ΦPL = 18.5%. We note that the emission from CDs@SiO2 originates from the intrinsic luminescent centers of CDs immobilized within the rigid Si-O network, and the emission intensity scales with CD concentration.

PMID 42662742
Read full article →
PubMedVaccine2026-08-28

Immunogenicity of type 2 novel oral poliovirus vaccine administered in outbreak response, Kenya 2023: an observational cohort study.

Anand Abhijeet A, Jepkosgei Damaris D, Mwachari Christina C, Jalang'o Rose R et al.

In 2023, novel oral polio vaccine type 2 (nOPV2) was used to respond to an outbreak of circulating vaccine-derived poliovirus type 2 (cVDPV2) in Kenya. We assessed the immunogenicity of one and two doses of nOPV2 administered during outbreak response. An observational cohort study was conducted from October to December 2023 in Kitui and Tana River counties in Kenya. Children aged 6-59 months were enrolled. Two nOPV2 doses were administered. Dried blood spots (DBS) were collected at enrollment, four-weeks after the first nOPV2 dose, and two- and four-weeks after the second nOPV2 dose. The DBS cards were tested at the US Centers for Disease Control and Prevention (CDC), Atlanta for the presence of poliovirus neutralizing antibodies using microneutralization assays. The primary endpoint was cumulative immune response after two nOPV2 doses. Of the 475 participants followed in the study, 461 (97%) completed all study visits and were included in the analysis. Four weeks after two nOPV2 doses, a cumulative type 2 immune response was observed in 285 (62%; 95% CI 57-66) of 461 participants. After one nOPV2 dose, type 2 immune response was observed in 196 (43%, 95% CI 38-47) of 461 participants. Type 2 seropositivity (titers ≥1:8) increased from 19% at enrollment to 72% after two nOPV2 doses. The study demonstrated an immune response in 62% of the participants following two nOPV2 outbreak vaccination rounds. These findings suggest that two nOPV2 doses may be insufficient to achieve high population immunity during poliovirus type 2 outbreak response in sub-Saharan Africa.

PMID 42664529
Read full article →
PubMedFrontiers in cardiovascular medicine2026-08-28

Elevated urinary sodium thresholds in high-salt diet heart failure: implications for diuretic resistance diagnosis.

Ji Xiaotong X, Gao Zheng Z, Ma Zhiyuan Z, Li Lizhuo L et al.

Urinary sodium has been widely validated as a biomarker for diagnosing diuretic resistance (DR) in heart failure (HF) patients in Western populations; however, its role in DR Diagnosis and HF management remains unclear in high-sodium dietary regions such as northern China. In this single-center, prospective cohort study, from November 2021 to March 2024, 285 consecutive patients with acute decompensated HF (ADHF) received intravenous furosemide >80 mg/day. DR was defined as persistent fluid retention despite adequate diuretic dosing (>80 mg/day IV furosemide or equivalent), inadequate urine output (<0.5-1 mL/kg/h), or insufficient weight loss (<0.5-1 kg/day). Their urinary sodium concentrations at baseline, and at 1, 2, and 3-6 h post-administration of a 40 mg intravenous furosemide bolus were recorded. In total, 177 patients were with DR and 108 non-DR. Both DR and non-DR groups exhibited markedly elevated 24-hour urinary sodium compared to western populations (130.3 in DR and 161.46 mmol/24 h in non-DR). ROC analysis indicated optimal thresholds of spot urinary sodium <85.8 mmol/L (AUC=0.791) and 1-hour post-dose urinary sodium <98.7 mmol/L (AUC=0.915) for diagnosing DR, outperforming traditional metrics. Low urinary sodium levels (spot <55.2 mmol/L, 1-hour <87.3 mmol/L) independently predicted all-cause mortality (AUC: 0.656 and 0.654, respectively). In high dietary sodium regions, urinary sodium thresholds for diagnosing DR are significantly higher than the western population, emphasizing the need for region-specific urinary sodium thresholds in such population.

PMID 42661887
Read full article →
PubMedInsects2026-08-27

A DNA Barcode Reference Library for Trichoptera of Jingpo Lake: Taxonomic Diversity and Molecular Identification Basics.

Xie Tongyin T, Chai Lu L, Zhang Ni N, Wang Na N et al.

Jingpo Lake in Northeast China is a vital aquatic ecosystem, yet it lacks baseline molecular data for its insects. Trichoptera (caddisflies) are excellent ecological bioindicators, but their accurate identification is often hindered by morphological similarities, life-stage limitations, and insufficient DNA barcode records. To address this gap, this study combined morphological identification with DNA barcoding to establish a local reference database. From 285 collected adult caddisflies, 105 representative specimens were selected for genetic analysis. The survey identified 22 species across 9 families, revealing four new records for China and six for Heilongjiang Province. Analyses confirmed the high efficacy of the COI marker, demonstrating low intraspecific genetic divergence (0.78%) and high interspecific divergence (17.80%), with a clear barcode gap separating all examined species. Species accumulation curves indicated robust sampling of the main genera, although expanded collection efforts could still uncover additional species. In conclusion, this study provides a valuable DNA barcode reference library for Trichoptera in the Jingpo Lake region. It establishes foundational data for regional biodiversity inventories and future ecological monitoring based on environmental DNA (eDNA) or metabarcoding approaches.

PMID 42652511
Read full article →
PubMedResearch in sports medicine (Print)2026-08-27

Training activities associated with lumbar pain exacerbation in competitive swimmers with prior lumbar spine injury: a cross-sectional survey.

Xu Emily E, Hsu Connie C, Liu Kaitlyn K, Benjamin Holly H et al.

Competitive swimmers often accumulate high training volumes that place repetitive stress on the lumbar spine, potentially worsening injury and pain. This study examined training activities associated with self-reported lumbar spine pain exacerbation in competitive swimmers with prior lumbar spine injury. We conducted a retrospective cross-sectional survey of 285 swimmers (mean age 18.7 ± 3.1 years) assessing demographics, training exposures, and injury history. 29 swimmers (10.2%) reported a prior lumbar spine injury, including disc pathology (20.7%), spondylolysis/spondylolisthesis or facet pain (27.6%), lumbar strain (27.6%), and scoliosis or sacroiliac pain (24.1%). All activity-related analyses were conducted on these 29 swimmers. The frequency of self-reported pain exacerbation differed significantly across the 12 training activities (Cochran's Q(11) = 80.02, p < 0.001). Butterfly (86.2%), dryland strength training (75.9%), and turns (72.4%) were most frequently reported as pain-provoking, whereas paddles (13.8%) and pull buoys (13.8%) were least frequently reported as pain-provoking. Among competitive swimmers with a history of lumbar spine injury, the frequency of reported pain exacerbation varied across training activities, with butterfly, turns, and dryland strength training most frequently reported as exacerbating symptoms. These findings can inform practical activity-modification strategies and may inform future prospective studies evaluating activity modification and return-to-swimming strategies in swimmers with lumbar spine pain.

PMID 42656138
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Hoe-285